CD14 and neoplasm: Based on our prior finding on the potent immunostimulatory effect of ΔM062R in monocytes and macrophages [18,43], we further examined whether the immunotherapeutic benefit of ΔM062R is due to its effects on the immunosuppressive tumor-associated monocyte/macrophage population in the tumor environment, designated immunosuppressive CD14+ tumor-associated macrophages (TAMs).